Vitamin E con- sumption and the risk of coronary disease in women. N Engl J Med. 1993;328:1444 9. 838. Vivekananthan DP, Penn MS, Sapp SK, et al. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet. 2003;361:2017 23. 839. Homocysteine and risk of ischemic heart disease and stroke: a meta- analysis. JAMA. 2002;288:2015 22. 840. Arnesen E, Refsum H, Bonaa KH, et al. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 1995;24:704 9. 841. Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230 6. 842. Villarruz MV, Dans A, Tan F. Chelation therapy for atherosclerotic cardiovascular disease. Cochrane Database Syst Rev. 2002; CD002785. 843. Abrams J. Clinical practice. Chronic stable angina. N Engl J Med. 2005;352:2524 33. 844. Wight LJ, VandenBurg MJ, Potter CE, et al. A large scale comparative study in general practice with nitroglycerin spray and tablet formu- lations in elderly patients with angina pectoris. Eur J Clin Pharmacol. 1992;42:341 2. 845. VandenBurg MJ, Wight LJ, Griffiths GK, et al. Sublingual nitroglyc- erin or spray in the treatment of angina. Br J Clin Pract. 1986;40: 524 7. 846. Rousseau MF, Pouleur H, Cocco G, et al. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol. 2005;95:311 6. 847. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized con- trolled trial. JAMA. 2004;291:309 16. 848. Stone PH, Gratsiansky NA, Blokhin A, et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48:566 75. 849. 